About us
Overview
A bold vision for the future of antibody therapeutics.
Through advanced protein engineering, we've developing new generation of antibody-based therapeutics – with an initial focus on TNF receptor (TNFR) agonism and infectious diseases – that influence complex biology in ways that have never been possible.
Our Multabody™ platform brings multiple antibody binding domains together on a three-dimensional scaffold. By tuning how these domains engage and interact with biological targets, we can control the signals and responses that follow.
Pursuing high-value therapeutic opportunities
We are advancing a pipeline of Multabody™ therapeutics including TNFR agonists targeting 4-1BB, the master regulator of T cell durability, and DR5, an unsolved therapeutic target in cancer. Our HIV program is designed to target latent viral reservoirs and deliver broad neutralization.
> SEE OUR PIPELINE
This creates the opportunity to:
Activate receptors to stimulate
desired biological activity.
Inhibit targets or pathways to dampen underlying disease mechanisms.
Coordinate complementary biological mechanisms within a single therapeutic molecule.
> VIEW OUR PLATFORM
While conventional antibodies have transformed medicine, they are limited in their ability to engage complex biological targets. Radiant is going beyond these limitations.